Promising Radioimmunotherapy Option for Some Lymphomas Cancer Network A phase I/II study found that radioimmunotherapy with 177Lu and the anti-CD20 antibody rituximab along with the chelator DOTA is safe and feasible for treatment of relapsed follicular, mantle cell, or other indolent lymphomas. “Radioimmunotherapy ... |
